You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Bullet Proof vascular graft to prevent dialysis access cannulation injury

    SBC: Innavasc Medical, Inc.            Topic: 400

    Project Summary Abstract Synthetic arteriovenous grafts AVGs can provide life sustaining vascular access for dialysis patients but are subject to multiple modes of failure and complications related to chronic needle cannulation poor graft identification delayed access and bleeding These graft needle cannulation associated complications translate to millions of dollars in health care expense ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioid dependent patients Over million people in the US are addicted to opiates Providing effective agonist therapy methadone or buprenorphine coupled with behavioral counseling greatly improves outcomes reduces morbidity and reduces societal costs Methadone maintenance treatment has been limit ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A novel protein engineering tool for rapid manufacturing of designer nucleosomes

    SBC: Epicypher, Inc.            Topic: 103

    PROJECT SUMMARY Nucleosomes are the basic building blocks of chromatin and composed of bp DNA wrapped around a core histone octamer Chromatin function is controlled by the dynamic addition removal of histone post translational modifications PTMs Significantly alterations in specific PTMs are associated with changes in gene expression driving the emergence progression of many cancer ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. A Platform Technology for High-Throughput Screening of Gene Regulatory Elements

    SBC: Element Genomics, Inc.            Topic: 200

    Project Summary Abstract The goal of this proposal is to develop a novel high throughput platform for understanding gene regulatory elements in order to identify new drug targets for common diseases The human genome encodes approximately genes Understanding how those genes are regulated and how this correlates to complex cell phenotypes has long been a major focus of our team Follow up p ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells

    SBC: CELL MICROSYSTEMS INC            Topic: NIAID

    PROJECT SUMMARY Cell Microsystems Inc is an early stage biotechnology company whose mission is the commercialization of a novel cost effective platform enabling the identification and efficient isolation of viable cells based on morphologic and fluorescence signatures as well as characteristics that change over time The CellRaft technology is based on a unique cell array recently developed ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Delivery of pathogen trapping antibodies for vaginal protection

    SBC: MUCOMMUNE, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Despite immense efforts in behavioral interventions to promote safer sexual practices sexually transmitted infections STIs continue to be a pandemic worldwide Unfortunately there are no effective vaccines or microbicides for the majority of STIs A pathogen specific safe effective and discreet vaginal microbicide that does not require daily or sex associ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Drug Activation of HSF1 for Prevention of Noise-Induced Hearing Loss

    SBC: CHAPERONE THERAPEUTICS, INC.            Topic: NIDCD

    PROJECT SUMMARY The studies proposed here address a significant health issue the high incidence of acquired deafness from noise overstimulation that can result from recreational and workplace related activities and from service in the military Through a robust academic pharma partnership between investigators at the Kresge Hearing Research Institute with long standing interests and expertise in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Human nasal epithelial organoids as a non-invasive, personalized model for predicting effectiveness of CFTR modulators in cystic fibrosis patients

    SBC: Path BioAnalytics, Inc.            Topic: ABC

    DESCRIPTION provided by applicant The discovery of the single gene CFTR cause of cystic fibrosis CF has been transformational focusing treatment on modulator drugs that restore function of the CFTR gene product CFTR andquot correctorsandquot enhance transport of mutant protein to the cell membrane and CFTR andquot potentiatesandquot activate mutant protein that does get to the membrane ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Nasal Leptin- Polymer Conjugate for Treatment of Obesity

    SBC: NEURO10-9 PHARMA INC            Topic: 300

    DESCRIPTION provided by applicant Despite their increased risk of developing serious diseases including coronary heart disease Type diabetes hypertension certain types of cancers and stroke the public health crisis of individuals who are overweight or obese continues unabated Safety issues have hampered development of drugs designed to control weight and the four drugs currently on the ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government